LTC2203431I2 - Priešinfekciniai pirimidinai ir jų panaudojimas - Google Patents

Priešinfekciniai pirimidinai ir jų panaudojimas

Info

Publication number
LTC2203431I2
LTC2203431I2 LTPA2015013C LTPA2015013C LTC2203431I2 LT C2203431 I2 LTC2203431 I2 LT C2203431I2 LT PA2015013 C LTPA2015013 C LT PA2015013C LT PA2015013 C LTPA2015013 C LT PA2015013C LT C2203431 I2 LTC2203431 I2 LT C2203431I2
Authority
LT
Lithuania
Prior art keywords
pyrimidines
infectious
crystalline forms
dihydropyrimidin
methanesulfonamide
Prior art date
Application number
LTPA2015013C
Other languages
English (en)
Lithuanian (lt)
Original Assignee
Abbvie Bahamas Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Bahamas Limited filed Critical Abbvie Bahamas Limited
Publication of LTC2203431I2 publication Critical patent/LTC2203431I2/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/225—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
LTPA2015013C 2007-09-17 2015-03-04 Priešinfekciniai pirimidinai ir jų panaudojimas LTC2203431I2 (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97288107P 2007-09-17 2007-09-17
US9679208P 2008-09-13 2008-09-13
PCT/US2008/076592 WO2009039134A1 (en) 2007-09-17 2008-09-17 Anti-infective pyrimidines and uses thereof

Publications (1)

Publication Number Publication Date
LTC2203431I2 true LTC2203431I2 (lt) 2017-01-25

Family

ID=40308557

Family Applications (1)

Application Number Title Priority Date Filing Date
LTPA2015013C LTC2203431I2 (lt) 2007-09-17 2015-03-04 Priešinfekciniai pirimidinai ir jų panaudojimas

Country Status (21)

Country Link
US (3) US8188104B2 (enExample)
EP (3) EP2203431B1 (enExample)
JP (3) JP5734655B2 (enExample)
CN (4) CN101842360B (enExample)
AT (1) ATE519746T1 (enExample)
CA (2) CA2849420C (enExample)
CY (3) CY1115514T1 (enExample)
DK (3) DK2203431T3 (enExample)
ES (3) ES2523864T3 (enExample)
HR (2) HRP20110809T1 (enExample)
HU (1) HUS1500013I1 (enExample)
LT (1) LTC2203431I2 (enExample)
LU (1) LU92666I2 (enExample)
MX (1) MX2010002902A (enExample)
NL (1) NL300729I1 (enExample)
NO (1) NO2015011I1 (enExample)
PL (3) PL2368882T3 (enExample)
PT (3) PT2368882E (enExample)
RU (2) RU2014147354A (enExample)
SI (2) SI2203431T1 (enExample)
WO (1) WO2009039134A1 (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20110809T1 (hr) * 2007-09-17 2011-12-31 Abbott Laboratories Protuupalni pirimidini i njihove uporabe
EP2548873A1 (en) 2007-09-17 2013-01-23 Abbott Laboratories N-phenyl-dioxo-hydropyrimidines useful as hepatitis c virus (hcv) inhibitors
ES2453591T3 (es) 2007-09-17 2014-04-08 Abbvie Bahamas Ltd. Derivado de uracilo o timina para el tratamiento de la hepatitis C
PE20110409A1 (es) * 2008-07-23 2011-06-22 Hoffmann La Roche Compuestos heterociclicos antiviricos
BRPI0920513A2 (pt) 2008-09-26 2019-09-24 F Hoffamann La Roche Ag derivados de pirina ou pirazina para tratar hcv
WO2010043721A1 (en) 2008-10-17 2010-04-22 Oryzon Genomics, S.A. Oxidase inhibitors and their use
WO2010084160A1 (en) 2009-01-21 2010-07-29 Oryzon Genomics S.A. Phenylcyclopropylamine derivatives and their medical use
WO2010111437A1 (en) * 2009-03-25 2010-09-30 Abbott Laboratories Antiviral compounds and uses thereof
EP2421831A1 (en) 2009-04-25 2012-02-29 F. Hoffmann-La Roche AG Heterocyclic antiviral compounds
AR077004A1 (es) 2009-06-09 2011-07-27 Hoffmann La Roche Compuestos heterociclicos antivirales
TW201103545A (en) 2009-06-24 2011-02-01 Hoffmann La Roche Heterocyclic antiviral compound
CA2768924A1 (en) 2009-09-21 2011-03-24 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
KR101736218B1 (ko) 2009-09-25 2017-05-16 오리존 지노믹스 에스.에이. 라이신 특이적 디메틸라아제-1 억제제 및 이의 용도
WO2011042217A1 (en) 2009-10-09 2011-04-14 Oryzon Genomics S.A. Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use
CA2778206A1 (en) * 2009-11-21 2011-05-26 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
BR112012014164A2 (pt) * 2009-12-14 2016-05-17 Merck Patent Gmbh inibidores da esfingosina quinase
TW201144298A (en) * 2009-12-14 2011-12-16 Hoffmann La Roche Heterocyclic antiviral compounds
WO2011106105A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Inhibitors for antiviral use
WO2011106106A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
US9216952B2 (en) 2010-03-23 2015-12-22 Abbvie Inc. Process for preparing antiviral compound
JP5868948B2 (ja) 2010-04-19 2016-02-24 オリゾン・ジェノミックス・ソシエダッド・アノニマＯｒｙｚｏｎ Ｇｅｎｏｍｉｃｓ Ｓ．Ａ． リジン特異的脱メチル化酵素１阻害薬およびその使用
US8975443B2 (en) 2010-07-16 2015-03-10 Abbvie Inc. Phosphine ligands for catalytic reactions
MX2013000623A (es) * 2010-07-16 2013-06-13 Abbvie Inc Proceso para la preparación de compuestos antivirales.
US9255074B2 (en) 2010-07-16 2016-02-09 Abbvie Inc. Process for preparing antiviral compounds
WO2012009698A1 (en) 2010-07-16 2012-01-19 Abbott Laboratories Phosphine ligands for catalytic reactions
EP3375775A1 (en) 2010-07-29 2018-09-19 Oryzon Genomics, S.A. Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use
EP2598480B1 (en) 2010-07-29 2019-04-24 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as lsd1 inhibitors
WO2012020725A1 (ja) * 2010-08-10 2012-02-16 塩野義製薬株式会社 Ｎｐｙ ｙ５受容体拮抗作用を有するヘテロ環誘導体
US9061966B2 (en) 2010-10-08 2015-06-23 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012072713A2 (en) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
EP2712315B1 (en) 2011-02-08 2021-11-24 Oryzon Genomics, S.A. Lysine demethylase inhibitors for myeloproliferative disorders
CN102675092B (zh) * 2011-03-14 2014-11-05 江苏中丹药物研究有限公司 一种制备2-芳基-2,2-二甲基乙酸甲酯的方法
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US9487512B2 (en) 2011-10-20 2016-11-08 Oryzon Genomics S.A. (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
IL264982B (en) 2011-10-20 2022-08-01 Oryzon Genomics Sa Hetero(aryl)cyclopropylamine compounds as lsd1 inhibitors
EA201490837A1 (ru) 2011-10-21 2014-11-28 Эббви Инк. Способы лечения hcv, включающие по меньшей мере два противовирусных агента прямого действия, рибавирин, но не интерферон
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
AU2013201532B2 (en) * 2011-10-21 2014-10-02 Abbvie Ireland Unlimited Company Methods for treating HCV
WO2014031791A1 (en) 2012-08-21 2014-02-27 Abbvie Inc. Process for preparing antiviral compounds
EP2908808A1 (en) 2012-10-18 2015-08-26 Abbvie Inc. Formulations of pyrimidinedione derivative compounds
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
CN106065009B (zh) * 2014-06-28 2019-03-01 广东东阳光药业有限公司 作为丙型肝炎抑制剂的化合物及其在药物中的应用
WO2016105547A1 (en) 2014-12-24 2016-06-30 Concert Pharmaceuticals, Inc. Deuterated dasabuvir
EA036086B1 (ru) * 2016-03-17 2020-09-24 Фмк Корпорейшн Способ превращения s-энантиомера в его рацемическую форму
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
WO2017202207A1 (zh) * 2016-05-27 2017-11-30 深圳市塔吉瑞生物医药有限公司 一种取代的萘环化合物及药物组合物及其应用
CN110483496B (zh) * 2019-07-17 2021-05-04 杭州市西溪医院 一类具有尿嘧啶-苯并噻唑结构衍生物、其制备方法及抗hcv药物的应用
CN111518036A (zh) * 2020-04-29 2020-08-11 杭州勇诚睿生物科技有限公司 一种达沙布韦关键中间体的制备方法
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors
CN117466847B (zh) * 2022-07-22 2026-01-27 中国医药工业研究总院有限公司 一种利非斯特中间体苯并呋喃-6-羧酸的制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4239888A (en) * 1974-11-04 1980-12-16 Pfizer Inc. 1-Phenyluracils
JPS60243017A (ja) * 1984-05-16 1985-12-03 Kyowa Hakko Kogyo Co Ltd 抗けいれん組成物
AU627906B2 (en) * 1989-07-14 1992-09-03 Nissan Chemical Industries Ltd. Uracil derivatives and herbicides containing the same as active ingredient
US5084084A (en) * 1989-07-14 1992-01-28 Nissan Chemical Industries Ltd. Uracil derivatives and herbicides containing the same as active ingredient
DE69129998T2 (de) * 1990-02-15 1998-12-24 Takeda Chemical Industries, Ltd., Osaka Pyrimidindionderivate, deren Herstellung und Verwendung
NL9001075A (enExample) * 1990-05-04 1991-12-02 Duphar Int Res
EP0489480A1 (en) * 1990-12-05 1992-06-10 Nissan Chemical Industries Ltd. Uracil derivatives and herbicides containing the same as active ingredient
JPH05213755A (ja) 1992-02-07 1993-08-24 Nikko Kyodo Co Ltd 肝臓障害治療薬
DE19528305A1 (de) 1995-08-02 1997-02-06 Bayer Ag Substituierte Phenyluracile
US6380387B1 (en) * 1999-12-06 2002-04-30 Hoffmann-La Roche Inc. 4-Pyrimidinyl-n-acyl-l phenylalanines
AU783348B2 (en) 1999-12-06 2005-10-20 F. Hoffmann-La Roche Ag 4-pyrimidinyl-N-acyl-L-phenylalanines
IL167955A (en) * 2000-02-04 2007-10-31 Sumitomo Chemical Co Inilines are converted by troiril
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
NZ534811A (en) * 2002-02-14 2007-07-27 Pharmasset Inc Modified fluorinated nucleoside analogues
RS20050363A (sr) * 2002-11-28 2007-11-15 Schering Aktiengesellschaft, Chk-,Pdk- I Akt-INHIBITORNI PIRIMIDINI, NJIHOVA PROIZVODNJA I UPOTREBA KAO FARMACEUTSKIH SREDSTAVA
KR100589964B1 (ko) * 2003-06-13 2006-06-19 주식회사 엘지생명과학 Ｃ형 간염 바이러스의 억제제
EP1651631A1 (en) * 2003-08-01 2006-05-03 Genelabs Technologies, Inc. Bicyclic imidazol derivatives against flaviviridae
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
KR20070083484A (ko) * 2004-07-14 2007-08-24 피티씨 테라퓨틱스, 인크. Ｃ형 간염 치료 방법
AR057986A1 (es) * 2005-11-21 2008-01-09 Japan Tobacco Inc Compuesto heterociclico y su uso farmaceutico
HRP20110809T1 (hr) * 2007-09-17 2011-12-31 Abbott Laboratories Protuupalni pirimidini i njihove uporabe
ES2453591T3 (es) * 2007-09-17 2014-04-08 Abbvie Bahamas Ltd. Derivado de uracilo o timina para el tratamiento de la hepatitis C
EP2548873A1 (en) 2007-09-17 2013-01-23 Abbott Laboratories N-phenyl-dioxo-hydropyrimidines useful as hepatitis c virus (hcv) inhibitors
PE20110409A1 (es) 2008-07-23 2011-06-22 Hoffmann La Roche Compuestos heterociclicos antiviricos

Also Published As

Publication number Publication date
CA2699986C (en) 2014-06-17
CN101842360A (zh) 2010-09-22
SI2203431T1 (sl) 2011-12-30
WO2009039134A1 (en) 2009-03-26
HRP20110809T1 (hr) 2011-12-31
EP2203431B1 (en) 2011-08-10
JP2013056886A (ja) 2013-03-28
EP2639226B1 (en) 2016-08-31
JP2015187106A (ja) 2015-10-29
HK1148273A1 (en) 2011-09-02
CY1115514T1 (el) 2016-04-13
RU2010114827A (ru) 2011-10-27
CN102746240B (zh) 2017-10-03
SI2368882T1 (sl) 2015-02-27
RU2014147354A (ru) 2015-07-10
HK1156033A1 (en) 2012-06-01
NO2015011I2 (no) 2015-04-22
MX2010002902A (es) 2010-06-02
ATE519746T1 (de) 2011-08-15
NL300729I2 (enExample) 2016-01-07
PT2639226T (pt) 2016-12-09
CA2849420A1 (en) 2009-03-26
RU2014147354A3 (enExample) 2018-07-30
US9139536B2 (en) 2015-09-22
JP5734655B2 (ja) 2015-06-17
PL2368882T3 (pl) 2015-04-30
EP2368882B1 (en) 2014-08-13
CA2699986A1 (en) 2009-03-26
PL2203431T3 (pl) 2012-01-31
HRP20141102T1 (en) 2015-03-13
CY2015013I2 (el) 2016-04-13
PT2203431E (pt) 2011-10-12
EP2639226A1 (en) 2013-09-18
CY1115893T1 (el) 2017-01-25
EP2203431A1 (en) 2010-07-07
US20090186912A1 (en) 2009-07-23
CY2015013I1 (el) 2016-04-13
RU2539570C2 (ru) 2015-01-20
US8188104B2 (en) 2012-05-29
DK2639226T3 (en) 2016-12-19
EP2368882A1 (en) 2011-09-28
US8501238B2 (en) 2013-08-06
PL2639226T3 (pl) 2017-02-28
US20140294766A1 (en) 2014-10-02
ES2368879T3 (es) 2011-11-23
DK2203431T3 (da) 2011-11-21
ES2523864T3 (es) 2014-12-02
HUS1500013I1 (hu) 2016-11-28
JP2010539187A (ja) 2010-12-16
NL300729I1 (enExample) 2016-01-07
CN104628655A (zh) 2015-05-20
CN102746240A (zh) 2012-10-24
DK2368882T3 (en) 2014-12-01
US20120244119A1 (en) 2012-09-27
JP5931683B2 (ja) 2016-06-08
CN101842360B (zh) 2014-12-17
ES2592961T3 (es) 2016-12-02
CA2849420C (en) 2016-07-12
PT2368882E (pt) 2014-11-27
LU92666I2 (fr) 2015-11-24
CN104628654A (zh) 2015-05-20
NO2015011I1 (no) 2015-05-04

Similar Documents

Publication Publication Date Title
LTC2203431I2 (lt) Priešinfekciniai pirimidinai ir jų panaudojimas
EA200970575A1 (ru) Соединения на основе 4-фенил-6-(2,2,2-трифтор-1-фенилэтокси)пиримидина и способы их применения
ATE482953T1 (de) Hiv-inhibierende 5-(hydroxymethylen- und aminomethylen) substituierte pyrimidine
MX2008012576A (es) Pirimidinas 5-amido sustituidas inhibidoras del virus de inmunodeficiencia humana.
TW200800968A (en) Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
NO20070655L (no) 2,4,6-Trisubstituerte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse ved behandling av kreft
CL2013000372A1 (es) Compuestos derivados de 1-fenil(dihidropirimidina/pirimidina)-2,4(1h,3h)-diona; forma cristalina de n-(6-(3-tert-butil-5-(2,4-dioxo-3,4-dihidropirimidin-1(2h)-il-metoxifenil)naftalen-2-il)metansulfonamida; proceso de preparacion;composicion farmaceutica; y su uso como antiviral para vhc (divisional cl 2794-08)
DK1723144T3 (da) Yderligere heteropolycykliske forbindelser og anvendelse deraf som metabotropiske glutamareceptor-antagonister
NO20075074L (no) Kinazolinon T-type-kalsiumkanalantagonister
MXPA05011643A (es) 5,7-diaminopirazolo[4,3-d]pirimidinas en el tratamiento de hipertension.
MX2009005363A (es) Pirimidinas y su uso como antagonistas del receptor cxcr2.
PL1869056T3 (pl) Nowe 5-podstawione pochodne 7-amino-[1,3]tiazolo[4,5-d]pirymidyny
DK1789398T3 (da) 2-amino-quinazolin derivater anvendelige som inhibitorer af B-sekretase (BACE)
NO20075218L (no) Dermatological compositions and salts for the treatment of dermatological diseases
DE602007010038D1 (de) Pyrimidylderivate als proteinkinaseinhibitoren
GT200600349A (es) Compuestos orgánicos
WO2007057742A3 (en) Novel piperazinone derivatives
MY140858A (en) Ampa receptor potentiators
DK1893597T3 (da) AMPA-receptorpotentiatorer